The global conversation around obesity and metabolic disease has shifted rapidly in recent years. Once dominated by lifestyle advice and modestly effective medications, it is now defined by powerful injectable therapies that can rival some of the benefits of bariatric surgery.
Semaglutide and tirzepatide have already changed the landscape. The next candidate waiting in the wings is retatrutide, an investigational drug from Eli Lilly that many researchers believe could go even further.
Retatrutide is a triple-agonist – a single molecule that activates three hormone receptors at once: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. This combination is designed not only to suppress appetite and improve blood sugar control, but also to raise energy expenditure and accelerate fat burning, particularly in the liver and visceral fat stores.
Paid Advertising
As of late 2025, retatrutide is still in phase 3 clinical trials and has not been approved for routine use. However, results from phase 2 studies, early phase 3 readouts, meta-analyses and body-composition sub-studies have attracted extraordinary attention. Taken together, they suggest this drug may deliver deeper weight loss and more comprehensive metabolic benefits than any current therapy – if longer-term safety and effectiveness are confirmed.
To understand why retatrutide is generating such interest, it helps to look briefly at its mechanism.
Current headline medications such as semaglutide and tirzepatide work by mimicking “incretin” hormones released by the gut after meals. These hormones tell the brain that the body has eaten, slow gastric emptying, and stimulate the pancreas to release insulin. The result is reduced appetite, smaller food intake and better blood sugar control.
Retatrutide goes a step further. Like tirzepatide, it acts on GLP-1 and GIP receptors, but it also activates glucagon receptors. Glucagon is often seen as the opposite of insulin, raising blood sugar by prompting the liver to release stored glucose. When carefully controlled and combined with GLP-1 and GIP signalling, however, glucagon can increase energy expenditure and fat oxidation, particularly in the liver. The theory – now strongly supported by early data – is that this triple action not only helps people eat less, but also encourages the body to burn off stored fat more aggressively.
The most striking results with retatrutide have come from phase 2 trials in people living with obesity, with and without type 2 diabetes.
Over a 48-week trial in adults with obesity but no diabetes, the highest tested dose of 12 mg once weekly produced an average 24.2% reduction in body weight, compared with just over 2% in the placebo group. In practical terms, this means a person starting at 120 kg could lose close to 29 kg on average over about a year, provided they tolerate and remain on the full dose.
Looking at a separate study of people with both obesity and type 2 diabetes, weight loss was understandably slightly lower – diabetes medications and metabolic differences often blunt the response – but still substantial. Participants receiving 8 mg weekly achieved around 17% weight loss over 36 weeks, with weight continuing to fall when follow-up was extended. Importantly, the majority of that loss came from fat mass rather than lean muscle, according to DEXA body-composition scans.
A 2025 meta-analysis pooling several phase 2 randomised controlled trials involving more than 500 participants confirmed these findings, showing 15–24% average weight loss across different doses and durations. Placebo groups, by contrast, lost only 2–3% of their weight. The analysis also suggested that retatrutide may outperform the dual-agonist tirzepatide for total fat-mass reduction, while preserving a similar proportion of lean tissue.
Early phase 3 data from the TRIUMPH programme have begun to extend this picture.
In one trial of people with obesity and knee osteoarthritis, top-line results released in late 2025 showed that those receiving 12 mg weekly achieved 22–26% average weight loss over 68 weeks, while the placebo group lost only around 2.5%.
Researchers noted that weight loss curves had not yet plateaued, raising the possibility that some patients may ultimately see 30% or more total body weight reduction with longer treatment.
While these are averages rather than guarantees, they indicate that retatrutide is operating in a range previously seen mainly with bariatric surgery, but through a weekly injection instead of an operation.
For people with type 2 diabetes, the promise of retatrutide lies in combining deep weight loss with meaningful improvements in blood sugar.
Phase 2 trials in participants with T2D have shown HbA1c reductions of 1.8–2.0 percentage points from baseline, with placebo-adjusted drops around 1.4 percentage points. That puts retatrutide in the same league as tirzepatide and clearly ahead of many older diabetes medications. Fasting glucose levels typically fall by 50–70 mg/dL, and measures of insulin resistance improve.
When directly compared with dulaglutide, an established GLP-1 agonist, retatrutide produced greater improvements in HbA1c, body weight and body-fat percentage, while maintaining a similar safety profile.
Early exploratory analyses suggest that 30–40% of participants in some trials may achieve formal diabetes remission criteria (near-normal HbA1c without additional glucose-lowering therapy), although these figures need to be confirmed in larger phase 3 populations.
The significance of this dual effect is not just cosmetic. Sustained weight loss and tighter glucose control can slow or even halt progression of T2D, reducing the risk of complications such as kidney disease, cardiovascular events and nerve damage.
One of the most compelling aspects of retatrutide’s profile relates to metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD (non-alcoholic fatty liver disease). MASLD occurs when fat accumulates in the liver and is now one of the most common liver conditions worldwide. It can progress to inflammation, fibrosis, cirrhosis and liver cancer.
In a dedicated MASLD substudy involving people with obesity and significant liver fat, retatrutide produced effects that many hepatologists considered unprecedented for a drug still in phase 2.
Participants entered the trial with an average liver fat content of around 20–25%, measured through MRI-proton density fat fraction (MRI-PDFF). After 24 weeks on 8 or 12 mg weekly, relative liver fat had fallen by more than 80%, and by week 48 it had dropped even further. In practical terms, liver fat levels fell to below 3–5% in nearly 90–93% of these patients, meaning that most no longer met the definition for fatty liver disease at all.
Lower doses still produced clinically meaningful improvements, but the highest doses essentially “de-fatted” the liver in the vast majority of participants. These reductions correlated strongly with overall weight loss and, crucially, with markers of liver inflammation and fibrosis. Experimental fibrosis scores improved or at least did not worsen in most participants, suggesting that early liver damage might be partially reversible with aggressive metabolic therapy.
When researchers compared these results indirectly with tirzepatide studies, the triple-agonist frequently came out ahead. Tirzepatide also reduces liver fat substantially, but typical relative reductions range from roughly 47–74% after a year, with resolution rates between 50–70%.
Whereas, retatrutide reached 81–86% reductions and nearly universal resolution in many patients, often in less than 12 months. The glucagon component, which directly stimulates hepatic fat oxidation, is thought to confer this advantage.
The implications are far-reaching.
MASLD is strongly linked to type 2 diabetes, cardiovascular disease, chronic kidney disease, certain cancers and even dementia.
Reducing liver fat from 20–25% to under 5% is associated in long-term cohort studies with significantly lower rates of heart attack, stroke, liver failure and overall mortality.
Beyond weight, blood sugar and liver health, retatrutide has attracted attention for potential effects on the brain.
Researchers increasingly refer to Alzheimer’s disease as a form of “type 3 diabetes” because insulin resistance and metabolic dysfunction in the brain appear to play a role in its progression. GLP-1 agonists such as semaglutide have shown early signs of neuroprotective benefit, including reduced brain shrinkage and possible reductions in dementia risk.
Retatrutide has not yet been tested in human trials for Alzheimer’s disease, and any talk of it being “life-changing” for dementia is speculative at this stage. However, preclinical studies in animal models are encouraging. In these models, triple-agonist therapy has been shown to reduce amyloid-β plaque build-up and tau pathology, dampen neuroinflammation, and improve brain insulin signalling and mitochondrial function. Because retatrutide also acts on glucagon receptors, it may further enhance neuronal energy metabolism.
For now, the Alzheimer’s field views retatrutide as a high-interest candidate rather than a proven therapy.
If its metabolic benefits translate into meaningful neuroprotection, future trials could position it as a medication that addresses both the systemic and brain-specific aspects of metabolic disease. Until those studies are completed, however, any such claims must remain cautious.
Given that both drugs are developed by the same company, direct comparisons between retatrutide and tirzepatide are inevitable.
Tirzepatide, a dual GLP-1/GIP agonist, is already approved as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It has demonstrated impressive weight-loss results of up to 21% in certain trials over 72 weeks and robust HbA1c improvements of up to 2.4 percentage points. It also has expanding real-world data and emerging cardiovascular outcome results.
Retatrutide, by contrast, remains investigational, with data extending to around 48–68 weeks so far. Indirect comparisons suggest:
- Weight loss: retatrutide appears capable of slightly greater average reductions (17–24% vs. 15–22.5%), with a quicker onset in some trials.
- Liver fat: retatrutide clearly leads, normalising fatty liver in close to 90% of cases in early studies.
- Diabetes control: both drugs produce sizeable HbA1c reductions, with tirzepatide currently backed by larger, longer T2D datasets.
- Safety: side-effect profiles are broadly similar, dominated by gastrointestinal symptoms such as nausea and diarrhoea. Retatrutide may have a slightly higher incidence of nausea, though discontinuation rates remain low for both.
A head-to-head phase 3 trial directly comparing the two medicines over 72 weeks is now under way, with results expected around 2027. That study should clarify whether retatrutide’s triple-agonist design translates into meaningful clinical advantages
Thus far, retatrutide’s safety profile broadly resembles that of other GLP-1-based therapies.
The most common adverse events are gastrointestinal: nausea, diarrhoea, vomiting and occasionally constipation. These side effects tend to appear during dose escalation, are dose-dependent, and often settle with time or slower titration. In phase 2 trials, discontinuation rates due to side effects ranged between 5–10%, which is considered acceptable for this drug class.
As with all incretin-based therapies, there is careful monitoring for rare but serious events such as pancreatitis, gallbladder disease and severe allergic reactions. To date, no major safety red flags unique to retatrutide have emerged, though it is still early in the drug’s lifecycle and longer-term data are essential.
Because retatrutide activates glucagon receptors, researchers are also watching for any unexpected impacts on heart rate, blood pressure and glucose levels. So far, no significant hypoglycaemia signal has been seen, likely because GLP-1 and GIP agonism counterbalance glucagon’s glucose-raising effect, but this remains an area of ongoing surveillance.
One of the most important messages emerging from retatrutide research is that reducing liver fat is not just a cosmetic achievement. It is a deeply disease-modifying intervention.
Therefore, when liver fat falls from around 20–25% to below 5%:
- Progression from simple steatosis to steatohepatitis and cirrhosis is often halted or reversed.
- The risk of hepatocellular carcinoma (liver cancer) falls markedly.
- Type 2 diabetes control improves, with higher remission rates and fewer complications.
- Cardiovascular risk drops as triglycerides, LDL cholesterol and inflammatory markers come down.
- Kidney function tends to stabilise more than in those with persistent fatty liver.
- Long-term observational studies suggest substantial reductions in all-cause mortality.
In some analyses, the health impact of resolving fatty liver approaches that of quitting smoking or effectively treating high blood pressure. Retatrutide’s ability to “de-fat” the liver quickly and thoroughly therefore has consequences that extend decades into a patient’s future.
At this stage, retatrutide remains an investigational therapy. It is not available for routine clinical use, and access is limited to those enrolled in clinical trials. Its striking benefits must still be weighed against long-term safety, durability of effect, cost and real-world practicality.
Nonetheless, the emerging data suggest that retatrutide could mark a new phase in the treatment of obesity-related disease. Rather than simply helping people lose weight, it seems capable of reshaping the underlying metabolic landscape: clearing excess fat from the liver, improving insulin sensitivity, lowering cardiovascular risk and possibly exerting protective effects in the brain.
If phase 3 trials confirm its promise, clinicians in the second half of this decade may have access to a tool that not only rivals surgery for weight loss, but also transforms the prognosis of diseases like metabolic liver disease and type 2 diabetes.
For now, anyone considering these developments should remember two key points. First, lifestyle measures – nutrition, movement, sleep, stress management and avoidance of harmful substances – remain the foundation of long-term metabolic health, regardless of medication.
Secondly, all medication-related decisions must be made in consultation with a suitably qualified healthcare professional, who can evaluate the risks, benefits, and available alternatives for each individual. This article is intended solely for educational purposes and should not be interpreted as an endorsement of this or any medical product.
Retatrutide is still a promising product if current trends continue, it may soon become one of the most important tools in modern metabolic medicine.
What are your thoughts on this? Do not be shy to let us know below.
Do not forget to read, What Is Type 5 Diabetes? Understanding the Newly Recognised Form of Malnutrition-Related Diabetes, if you missed it.
Looking for something a bit more phycological? Then give the following a read, You’re Not Crazy—The Internet Really Is Shaping How You See the World.
